Nemiralisib

DB16253InvestigationalSmall molecule

Nemiralisib is under investigation in clinical trial NCT03345407 (Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)).

Mechanism: Pharmacologically active on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Curator reviewed
Formula / weight: C₂₆H₂₈N₆O · 440.551 g/mol (avg)
Code names: GSK-2269557 · GSK-2269557A · GSK-2269557 FREE BASE

Resolves to

Compound

UNIIOEP8JJ3OZRCAS1254036-71-9ChEMBLCHEMBL2216859ChEBI754850PubChem49784002

Structure

InChIKeyMCIDWGZGWVSZMK-UHFFFAOYSA-NSMILESCC(C)N1CCN(CC2=CN=C(O2)C2=CC(=CC3=C2C=NN3)C2=CC=CC3=C2C=CN3)CC1

Targets

O00329PIK3CD

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Nemiralisib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account